326 related articles for article (PubMed ID: 18022018)
1. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
Dziemianko I; Jezior D; Boratyńska M; Patrzałek D; Kuźniar J; Szyber P; Klinger M
Transplant Proc; 2007 Nov; 39(9):2925-7. PubMed ID: 18022018
[TBL] [Abstract][Full Text] [Related]
2. Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.
Christensen EI; Zhou Q; Sørensen SS; Rasmussen AK; Jacobsen C; Feldt-Rasmussen U; Nielsen R
J Am Soc Nephrol; 2007 Mar; 18(3):698-706. PubMed ID: 17287429
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
4. Renal transplantation between siblings with unrecognized Fabry disease.
Taneda S; Honda K; Nakajima I; Huchinoue S; Oda H
Transplant Proc; 2013; 45(1):115-8. PubMed ID: 23375284
[TBL] [Abstract][Full Text] [Related]
5. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
Peces R; Olea T
Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
7. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
8. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
9. Fabry disease: molecular genetics of the inherited nephropathy.
Desnick RJ; Astrin KH; Bishop DF
Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
[TBL] [Abstract][Full Text] [Related]
10. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease.
Rosenthal D; Lien YH; Lager D; Lai LW; Shang S; Leung N; Fervenza FC
Am J Kidney Dis; 2004 Nov; 44(5):e85-9. PubMed ID: 15492942
[TBL] [Abstract][Full Text] [Related]
11. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease in hemodialysis patients in southern Brazil: prevalence study and clinical report.
Porsch DB; Nunes AC; Milani V; Rossato LB; Mattos CB; Tsao M; Netto C; Burin M; Pereira F; Matte U; Giugliani R; Barros EJ
Ren Fail; 2008; 30(9):825-30. PubMed ID: 18925518
[TBL] [Abstract][Full Text] [Related]
14. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
15. Chronic kidney disease is still present after renal transplantation with excellent function.
Bertoni E; Rosati A; Larti A; Merciai C; Zanazzi M; Rosso G; Gallo M; Marcucci R; Salvadori M
Transplant Proc; 2006 May; 38(4):1024-5. PubMed ID: 16757252
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.
Naganawa Y; Ohsugi K; Kase R; Date I; Sakuraba H; Sakuragawa N
Cell Transplant; 2002; 11(4):325-9. PubMed ID: 12162373
[TBL] [Abstract][Full Text] [Related]
17. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
18. Renal graft outcome in simultaneous kidney transplantation combined with other organs: experience of a single center.
Gutierrez-Baños J; Portillo J; Ballestero R; Zubillaga S; Ramos E; Campos J; Hidalgo E
Transplant Proc; 2008 Dec; 40(10):3424-7. PubMed ID: 19100404
[TBL] [Abstract][Full Text] [Related]
19. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
[TBL] [Abstract][Full Text] [Related]
20. Renal involvement in Anderson-Fabry disease.
Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
